Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis.Cancers · 2023
   Article
2. Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.Cancers · 2019
   Article
3. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.Archives of toxicology · 2017
   Review
4. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Advances in therapy · 2017
   Review
5. Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization.Oncoimmunology · 2016
   Article
6. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.Oncotarget · 2015
   Article
7. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Cancers · 2015
   Review
8. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.Blood cancer journal · 2013
   Article
9. Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.Haematologica · 2012
   Article
10. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.Molecular cancer · 2011
    Article
11. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.mAbs
    Review

Corrections and comments

• Comment on
  Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.2009
• Comment on
  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.2010

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as